Abstract
Background Preeclampsia (PE), a multi-systemic hypertensive pregnancy disease that affects 2-8% of pregnancies worldwide, is a leading cause of adverse maternal and fetal outcomes. Current clinical PE tests have a low positive predictive value for PE prediction and diagnosis. The placenta notably releases extracellular vesicles from the syncytiotrophoblast (STB-EV) into the maternal circulation.
Objective To identify a difference in placenta and STB-EV proteome between PE and normal pregnancy (NP), which could lead to identifying potential biomarkers and mechanistic insights.
Methods Using ex-vivo dual lobe perfusion, we performed mass spectrometry on placental tissue, medium/large and small STB-EVs isolated from PE (n = 6) and NP (n = 6) placentae. Bioinformatically, mass spectrometry was used to identify differentially carried proteins. Western blot was used to validate the identified biomarkers. We finished our investigation with an in-silico prediction of STB-EV mechanistic pathways.
Results We identified a difference in the STB-EVs proteome between PE and NP. Filamin B, collagen 17A1, pappalysin-A2, and scavenger Receptor Class B Type 1) were discovered and verified to have different abundances in PE compared to NP. In silico mechanistic prediction revealed novel mechanistic processes (such as abnormal protein metabolism) that may contribute to the clinical and pathological manifestations of PE.
Conclusions We identified potentially mechanistic pathways and identified differentially carried proteins that may be important in the pathophysiology of PE and are worth investigating because they could be used in future studies of disease mechanisms and as biomarkers.
Funding This research was funded by the Medical Research Council (MRC Programme Grant (MR/J0033601) and the Medical & Life Sciences translational fund (BRR00142 HE01.01)
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Medical Research Council (MRC Programme Grant (MR/J0033601) and the Medical & Life Sciences translational fund (BRR00142 HE01.01)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Oxfordshire Research Ethics Committee C (07/H0606/148) of the University of Oxford, United Kingdom gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This version has been revised to change the formatting of all tables and make the figure 2 easier to read.
Data Availability
All data produced are available online at https://data.mendeley.com/datasets/j2x4h9ddcj/draft?a=8ccd383c-c6e5-495d-b66b-29c691608995
https://data.mendeley.com/datasets/j2x4h9ddcj/draft?a=8ccd383c-c6e5-495d-b66b-29c691608995
